VTYX - Earnings call transcript Q1 2024 | Ventyx Biosciences, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good afternoon, ladies and gentlemen, and welcome to the Ventyx Biosciences First Quarter 2024 Earnings Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded.

I would now like to turn the call over to Dr. Martin Auster, Ventyx' Chief Financial Officer. Please begin.

Martin Auster

good everyone and us operator, you, afternoon joining to today. Thank corporate webcast Ventyx financial be a Biosciences to where results conference providing XXXX Welcome quarter call we'll first discussing and update. our

these XX, like materially to we of will XXXX, forward-looking A from for this cause and those These statements. actual I risks no of XX-Q Before are the and forward-looking March on call. any to recently statements that remind quarter Form statements projected. include we subject update was our begin, risks filed today's statements which ended afternoon. uncertainties that are in just found today's made everyone results today's assume forward-looking Any can to presentations made be only would obligation as may to description date, differ

that, the With ahead. Mohan, to Ventyx' please Dr. and now Raju over go CEO. Raju, hand Founder call I'll

Raju Mohan

everyone, earnings our and for for Yes. us thank and Thanks, call you, Marty, joining XXXX corporate quarter first update.

provided recently and be our Investor remarks a pipeline we As at today. will with my Day, brief strategic March I update full

Scientific Let our me then and the programs, minutes with take our review hand high-level Marty also provide financial Marty to We'll Officer. first Chief floor I'll where John to call to pipeline the back and again Q&A, by status joined the quarter a comments on open Nuss, be some results. few of to then our I'll

our with NLRPX positive multiple-ascending Phase in begin and novel our potential I NLRPX announced a VTXXXXX, healthy top trial volunteers. inhibitor I'll So from we of CNS-penetrant of adult dose In results best-in-class inhibitors. portfolio line March, single-

all both beta both as achieved coverage IL-X steady-state beta milligrams IL-X X CSF. once milligrams CSF plasma doses the you milligrams in remember, ICXX the as way up As coverage XX low QD, exceeded and and repeat to XX repeat well and doses of ICXX may VTXXXXX plasma daily in

that in target estimate to low XX-milligram modeling, in on ICXX dose and as be data CSF Based on VTXXXXX our once coverage doses daily the projection we beta these adequate IL-X plasma. may as achieve

observed showed in ex dose-dependent this I also tolerability -- stimulation vivo also excellent an robust We study. or whole PD in assay. excellent a And IL-X showed Phase profile blood pharmacodynamic VTXXXXX beta effects

II-ready believe excellent We, of potential VTXXXXX with convenient drug once-daily target regimen formulation. CSF, VTXXXXX thus, as This data our treatment Phase tablet conditions. these and profile candidate includes favorable plasma best-in-class in that diseases dosing establish a coverage compound. the and neuroinflammatory safety for and a oral is a

we trial which disease trials patients year. need, VTXXXXX As the VTXXXXX to also indications we in communicated with this Phase second with initiate will Phase advance half of March, plan of into rapidly the II with early in unmet in we in IIa high-value beginning substantial Parkinson's

NLRPX-mediated a of represents by discussed, neuronal we pathology degeneration. condition. in neurodegenerative approach As implicated devastating inhibition has preclinical therapeutic promising death NLRPX as growing evidence new impacting a of this inflammation We, key driver body believe that disease-modifying disease therefore, potentially a and Parkinson's

important potentially due loss also obese has buzz published in mice. of and showing much NLRPX and a for February as metabolic target weight it NLRPX-mediated much diseases, recently, last More central created data obesity discussion obesity-related to

obesity similar We of initiated studies in our about. model talked models VTXXXXX we own have neuroi the with diet-induced just to published

agonist these update exciting later GLP-X to VTXXXXX are These on induced combination with also study, weight providing assessing loss in to by and and we we're semaglutide monotherapy in addition the evaluating second studies quarter. a in an VTXXXXX look In with the studies, forward semaglutide.

II XXXX factors. of the cardiovascular trial participants now second risk initiate So to plan We of during moving half additional with humans. to from obese Phase in mice certain VTXXXXX a

our current from trial March, we VTXXXXX, with this moving to of In in our cryoprin-associated periodic restricted as VTXXXXX VTXXXXX peripherally A or biologics, fibrinogen. comparable IL-X, observed IL-X In with Now line high-sensitive of standard NLRPX serum inflammatory trial, syndromes results positive that care. such HSCRP, biomarkers demonstrated CAPS. also and to II CRP, inhibitor. Phase robust on top patients announced demonstrated VTXXXXX amyloid efficacy the reductions consistent in and

safety There VTXXXXX in inhibitor NLRPX-treated-related biomarkers XX% mild. for adverse peripheral a CAPS CAPS systemic all a in a and II inhibition general, mean of proof patients for data in was period including during for and patients the is, IL-X. Score Phase very These treatment-related therefore, for compelling mechanism reduction the of Key also our as graded events of Symptom these with treatment initial with favorable profile hsCRP

need. And March, represent we indications or cardiovascular VTXXXXX communicated on in and also unmet major with an in MACE. adverse prevention and events substantial medical development pericarditis focus pericarditis, future prevention indication for in initial secondary other evaluate as we cardiovascular MACE recurrent and to recurrent the markets large of RP, plan addressable and Both potentially with

our thus, an development plans in on plan we, update cardiovascular year. or provide to update So this later

our SXPX for in potential advancing allosteric modulator Beyond VTXXXX, TYKX Phase development of II ulcerative inhibitor for team Crohn's continues best-in-class receptor assets, our portfolio, and to colitis NLRPX progress including inhibitor disease. IBD make the the or treatment our VTXXXX,

potential October a includes XXXX, colitis. believe agent oral For we recall profile we VTXXXX, rate Phase profile. is endoscopic This and best-in-class of an that in differentiated demonstrating II announced positive highly you'll best-in-disease safety a potential for complete ulcerative remission of a in data what

that and from we the trial, for perhaps long-term for is III extension our the also ongoing. program II March part improved profile. to from anticipate the Phase endoscopic continue observed in data period. of show induction ready, the and extension of preliminary trial this II make event, Phase remission continue even the This Phase showed XX-week differentiated reinforcing data or XX-week endoscopic sustained open-label is preparations pivotal Phase will the teams remission fully III study to from our data the part further that the data At We

with meeting with this of advice scientific later conduct we EMA a expect productive the month, the meeting to completed and quarter. Last a Phase we X End FDA,

with continue to to completion we successful underway II are have efforts previously that trial pivotal completed a a trial pivotal this of have as indicated, We second to source sufficient other ulcerative of non-dilutive approval of partner III Phase And financing confidence be in identify VTXXXX to may colitis. our support or XX-week support trial. Phase

trial Finally, TYKX our VTXXXX, inhibitor our Phase Crohn's active moderately allosteric severe II progress. of disease to to continues and

quarter streamline in of year, in of to implemented As a amendment signal we've protocol this this mentioned the potential detection a efficacy first we trial.

now baseline XXX Crohn's in of the point at and XX. week index disease XX or approximately the change protocol result amendment, enrollment CDAI patients the trial's a the activity was from to main from primary patients, end approximately is revised As target score sole

to enrollment completed of reporting March, line early have and second half look top we in trial We forward results XXXX. in in the

So their members and I like and continued our to pipeline again all that in conclusion, across and the collaborators would in for contributions the across our our Ventyx all to trials. thank efforts team of investigators enroll patients

We a are updates. to productive for to looking much year continue and Ventyx provide to forward very these exciting

hand -- our now for financial call of a results. financial review of our brief I'll Marty quarter Marty? first the to back

Martin Auster

you, Raju. Thank Yes.

summarize release ended Our our are now. XX, issued briefly those March in XXXX, and results financial first I'll for results at here press quarter market close, the presented

first of were 'XX in and quarter compared million million first XXXX. quarter expenses to was for were net in first quarter of first a the our expenses of quarter the XXXX, $XX.X million the XXXX. of net $X.X to in G&A in to of first $XX.X quarter million million $X million compared loss R&D compared XXXX $XX.X $XX.X the loss quarter the in the

was $XXX.X XX, Our March cash, XXXX. balance cash million securities as marketable equivalents and of

Net is an higher cash and in the accrued during primarily of due the to $XX.X the operating quarter. increase prepaid $XX.X reported million expenses and used than expenses decrease during first operating of million in a activities in quarter expenses was

on operating get complete for as We operating wind-down remain and Phase into of expect lower we related rest second our as the flows II both in quarterly and of VTXXXX. to activities a to programs our psoriasis XXXX decrease and arthritis the psoriatic expenses our we XXXX basis trial quarter for cash

cash, our are to the and that least believe marketable equivalents to continue our support cash into We at second XXXX. current of planned operations sufficient securities half

now remarks session. the operator afternoon's Q&A begin I'll prepared call our the the back for to this to concludes call, and This turn

as ahead. session. joined Q&A Dr. be the Chief go by I'll our as Scientific please Mohan well Raju On Nuss. Operator, John Officer,

Operator

question first the And Yee with comes Instructions] from Jefferies. today [Operator Michael

Unknown Analyst

for This is Kyle Michael.

you promising And think an injectables the is on it human is do bar? So CNS this? stacks NLRPX what investigation? under you for do other think in the a study you what oral And up and options oral think do how like program, XX-day or

press Is be release? to it report mouse data. Where do in it quick format think are of the the a one the company? your going a present you you're to at going data? to And on Or going you

Raju Mohan

thanks. Well,

the address question second me first. let So

in late second it, we stay we're So so once the we mentioned I quarter. the for presenting that as And compiling the forum data all together, plan process we And just in we'll data. of -- report the what decide have right before, tuned. to this

modalities sort of GLP-X not from in with expect of days days, digits, human just as there, studies anywhere we in single weight what terms weight with out In to other about your X%, loss showing XX of see XX loss. agonist, there higher in question plenty to well, measurable trials was

out. show if competitor and to be remains again, put when data the it So the are seen data will what

we two there's -- diet obviously, One was we've we're study in things mice. obese published mind, have is, that repeating two our done these set the In happening. -- in

it's and and forward these looking compound semaglutide, As a study to results. mentioned, we're a monotherapy control, under with combination we with study it's reporting

we've And to trial in link think Parkinson's patients, parameters just mechanisms there NLRPX links dots such folks We're -- we of obesity that continue now that, it's to as and in control biology hypothalamic as linked own dots try grow activation NLRPX also, certainly or the of said, that it's will our been disease. to as for XX-day like behavior. trial, addition happening and there's I just to doing like feeding evidence committed body think the

from year. But when IIa seeing in We Phase planned, if own for patients then our committed this is, path put the which out and our we're to the doing latter study So here again, data put obese driving trial. the of there. it's the and forward competitor half is mouse look to out data

Operator

Rahimi Our Sandler. Yasmeen Piper with next comes question from

Liam Hiester

Yas. for on Hiester Liam is This

II order current II there? with my And needs guess first still in related done trial, pericarditis are initiate MACE is a on Phase to to to moving VTXXXXX? recurrent CD trial the available or initiating additional obese the with what those to expected and question trials, rate-limiting what then when then steps XXXX in the what's moving package to I patients be tox risk? And So for work Phase

Raju Mohan

All right.

start first the let So with me one.

a it's study. patients, our first These similar study a So is XX-day study.

are with the the We will year. early then the initiate disease. latter merits that we Phase in study of longer-term in planning the And if in XX-day studies Parkinson's half II the study particular obesity

we'll So on a year. right half study, the the we'll of package, do the now, to have support in and chronic the studies tox coverage tox latter XX-day then

on don't briefly, was one. the if question -- you Second repeating mind second

Liam Hiester

Yes.

I pericarditis? XXXX rate-limiting is like Phase what of initiation assay, trials So the for for the guess, recurrent II the MACE steps the and

Raju Mohan

trial We've for lay individual have be time the have laid has the every has written and get trial, lines done. and planning. to The -- time trials. to out no There's lines have cardiovascular Parkinson's protocols teams our the for we together, own its contracting obesity be out the the to to

step. been a It's I of a have rate-limiting a firmed Phase Phase still to planning those study. the study going II up, Once from just of there's process part

just secondary and opportunities cardiovascular pericarditis the XXXX, also excited it's standard both for recurrent But the So prevention pretty process here. have we of we're MACE. about in that in

Liam Hiester

question. Great. actually, one just And then more

with of like End if from you And of details meeting? Phase So any then interest. detail VTXXXX, the also on just X could more partnership level any provide wondering the

Raju Mohan

Yes.

the So have with we with meeting, discussion this the And a to progresses. of Phase believe should pivotal we'll trial a End one. good laid and justification trial dose. as as as on a we a had the -- continue a serve trial should the have Phase And single first our III agency meeting FDA, we X really the for with

in So FDA. a mind, very meeting our successful with the

not endoscopic we're specifics. into partnerships, this think continues strong In get to show very of We to compound a remission. terms going

a label, that both once the scores we of from precedent across we'll those support we midst progress to it even the long-term something as data of things and we And showed open pharma we interest guys will aggressively said, in are this extension to can of SXPX the getting believe from perhaps stay modulators. wide partners you continue the range update tuned. talk folks And as and improve durability we've with such As about.

Operator

Our H.C. next Wainwright. Emily from question Bodnar with comes

Emily Bodnar

bit can you're if study disease, any many symptoms. kind what how you curious evaluate? like design of if markers exclude on planning planning maybe I'm could in could you planning provide Parkinson's of For for to you're terms looking on if And evaluate. patients motor on are at more a you scores study? patients in obesity to comment impacts that And And to neurodegenerative you're disease-rating diabetes

Raju Mohan

Yes. Good question.

compound few again, to So a say, the competitor's saw again, this the disclose trial, a published it to have will of trial don't They it, We back. XX-day trial. context, -- just be trying biomarker on trial. ClinicalTrials.gov. we But we're not with Once NLRPX be and let's months you of it every in on specific aspect bring an cagey.

biomarker We see translates this also effects just content are a but and this as glial imaging have astrocytes trial not molecule to on of effects and an it eventually into we of eventual trial, death. planning neuro activation on component

one, much NLRPX-related expect but shown fibrinogen, trials, beta, multiple biomarkers, certainly them IL-X in such convincingly motor on see hsCRP, number effect the in we've Don't now on expect IL-X, we trials. these short to effects as symptoms

and showed the Phase early an trials I, markers peripheral even We in beta in we in hsCRP volunteers. some effects Even the -- a right? one in these in in again, So NLRPX we've biomarkers. even IL-X volunteers certainly NLRPX-treated movement these seen trial with albeit healthy compound, of response and in robust CSF, these showed in healthy and biomarkers are And the Phase XXXX, I also those on IL-X.

And such then particular a biomarkers. others of our other in you patients set measuring side is from markers much There of as light us chain precludes a have the again, Parkinson's that in neurodegenerative thoughtfully -- having nothing and with neurofilament strategy. and range in broader explore

be trial. again, we But effects meaningful of an setting why short these trials. end in Parkinson's months longer we're sort which longer published year, that of seen of much trial patients. or towards line will recently contemplating longer the a are have treatment expectation are the much what XX in of not more seeing or you've with for we any And that's And the

Operator

take our will Purohit Stanley. next with from We question Vikram Morgan

Gospel Enyindah-Asonye

This is Gospel on for Vikram.

the for continuing program. in based second We What is the hard [ regarding data the have of Crohn's question CD one disease your half VTXXXX ] on expected in year?

Raju Mohan

perhaps, let I'll address Marty Marty? Thanks, And Yes. Vikram. this.

Martin Auster

for Thanks Gospel. the Yes. question,

score for endpoints like endoscopic So secondary is that end we're and primary key trial, things point response then the at include like a change in and that CDI looking that.

If across products developed you're -- disease the some space, Crohn's of well like recent of look as approved in as biologics at sort the drugs upadacitinib. recently you more looking

meaningful sort double You'll range see a of type of CDI marker. the changes of the on II in upper kind in the hundreds response of digits low as Phase a to that kind of

of response. be the in high of that's endpoint secondary to the but type see there of looking again, given versus that a competitive response of, adequately the And sort something trial, the significance endoscopic side, be to versus delta endoscopic We're teens placebo. then we'd would in low relative size sort statistical XXs powered to detect on

So in think, sort kind drugs bar to where is setting. that's for of recently attractive this I be the approved of,

next the several to looking here we're months. forward those out in reporting results So

Operator

Alex We question will Stifel. from take our Thompson next with

Alexander Thompson

dose testing get follow bit both confident and the more XXXX going [ to you're combo equivalents on on you guess of in trial? see in little you mask human the ] I relative the about experiment. what little sort DIO first II? to what to the bit you're a to talk in for one up Can a Phase studies the be want monotherapy to looking And human

of And then inhibition indication what lutikizumab your you future? consider from just context at curious saw NLRPX on and the for AAD peripheral HS thoughts like XXXX, whether in we in the would an

Raju Mohan

Yes.

the mouse dose human on first in So equivalent study.

in the or of for to right? human goal. a the example, determine against it's the It's do dose. for in NLRPX on mice, compound the NLRPX. in, appropriately So these So we example, the anything don't the that's really else. in the proof-of-concept -- you And based profile of animals whether potency compound and mouse studies the for exposure not rodents, mouse mice, the It's dose

a beta the that's of Remember, IL-X if the biomarkers ICXX. cover trial or a IL-XX the that Phase and driver are we in the disease with drivers beta expect we've beta I is CSF. beta plasma and done calibrated to We've IL-X with have pathology, what ICXX, to and calibration. IL-X but IL-X in IL-XX, And trial exposure

do have in a of we the doses the then in by to aggregation, a surrogate. periphery in inhibition NLRPX what good CSF IL-X need So CNS, the and complete beta is humans produced complete or

the make clear, trial mouse So Phase for to find studies for trial. meant trial it doses just of are to not II Parkinson's obesity the any other a

So in again, on terms other it mice in that losses, the adequate we to the mice, coverage doses weight see on again compound. are sure effects and the set have make to now endpoints, of effects depends on see

So of in times we don't competitor-dosing take from paradigm was case any X which day sort it a in mice. guidelines the

regimen, that's therapy. combo in the dosing and have we've trials, monotherapy our We what the both done own and

to -- the had think have question what we is trial. a you expectation I see combination the expect you that in do

First shouldn't drug. which own the have really compound, trial trial, old of mice I we a of all, our to whole really -- study CNS our it a call is in this -- was calibration well-behaved

best the compound there in out penetrant I behaved CNS NLRPX think class. the

human are believe in is mice our calibration different which terms own parameters in set so And our to of predictive we models, disease. goal these of

is in aspects you recapitulate human obesity. different from this in and different not case mouse It's model studies, what a model. a expect it's right, readouts one-to-one this So study, human

So competitive of designed having having the we with no this expectation controls a a adequate with trial the but tight data, with placebo. the with sum control compound

see see many that loss. to you weight have you in It saw. compound, weight whether any compound loss the was published obviously been thing data First times. published With from semaglutide, our that's competitor

what Next HOMA-IR, thing lipid the to is once happens other diabetes effect steatosis. to parameters of insulin, understand what And weight effect glucose, to to completed, OGTT, intake. then parameters, happening study parameters, is of what's loss, like food happens

that. so know, we as benefit obesity on of reduction So parameters, number for in obesity in or results look we a

what In the the Is of on combo it NLRPX loss alone. study, synergistic? or obviously, monotherapy, Is but a effects of semaglutide inhibition GLP-agonist effect weight we for is just look not would vis-a-vis it alone additive?

Eventually, we'd this like to mechanism that understand orthogonal. is

pretty So again, in but interested the -- this to study of to in links human this microbial data cells, get think been a -- the exciting the we'll right? we're molecule way mouse the sort sort of of be built build lot really stage the whole a this So able vitro of done to like with this then work area. in this Parkinson's, of we're studies in we some committed new studies, mouse the understanding I in And doing obviously, And from to NLRPX studies. forefront our in Always but pathways. the a are pathway, opened dots. the we've part has connect

you to sharing end forward a mouse data in looking of the And second quarter. guys weeks, the few with

was... I third think your question

Martin Auster

in Potential for HS. XXXX

Raju Mohan

in Yes. Potential for XXXX HS.

bit encouraging, NLRPX were HS. well very, rilonacept, very isn't mechanism a potential -- example, clear for an as IL-X the that beta But there I such a there IL-X rationale explored. real you the analog there a AbbVie a results molecule the of AbbVie but be correspondence study enough antibody for looking that there's antibody canakinumab -- versus as in alpha to XXXX caution HS. as it's right? potential alpha has So a yes, PC there's area think such as, mechanism an trap, we certainly, So IL-X one-to-one just little at is beta for in beta between from

Operator

Derek our Archila Fargo. Wells with take question from next will We

Derek Archila

guess I a [indiscernible]. just couple on

And in to expect I [ what do is data positive [ ] think Parkinson's? also, you XXXX your from do trial to their getting Phase Ib/IIa, differentiate Phase then you've Given IIb in in XXXX you outcome in Phase seen your de-risked? ] now XXXX

Raju Mohan

Yes.

So if I bit. little -- a sorry, you fading were

data So that IIa Phase your Natera from Parkinson's the their in was the our was question? Yes. question has trial. Is de-risked

question. out any is from there for right? everything suitable the good compound. for that's an a showing study, the assume But of dosing see our data I we've It's where me study, effects Phase at in us, data the again, well-behaved this from let low believe on we drug doses. So QD been hasn't always extremely lot to there biomarkers seen, It's in class

to real have expect at ICXX And doses dosing profile. clean coverage XX milligrams. We of a kinetics it's starting at to single-order XX

I IL-X we'll to our have CSF, as study data. other light forward with looking in biomarkers beta, we're don't So respect markers on and to see well. own that effects hsCRP, in doubts this own Again, I establish generate and NLRPX. downstream XX-day we'll things IL-X beta both and like neurofilament and IL-X, any our Like profile blood chain said, biomarker

And Phase is was compound because well for But target have hard, our into the IIa go data from calibration we study. Phase a own so II some our behaved before set we'll that the there to we longer hit so Natera.

Operator

with Science. our Life Sam We Slutsky question will next from take

Samuel Slutsky

if I hopped let previously, me so know. of late, any answered you just a on tad my questions

anticipate it generally And with will or kind that conclusions than to good On loss? what obesity the kind the of Natera not weight looks were preclinical different the just bigger in just or speaking, there then did other how study from do is similar on of be XXXX, you preclinical any study? drawn methodology binary of that their it

Raju Mohan

for you. but so happy answers spent so. XX I don't about to in do hear repeat to you, and to I Yes. studies years much time Sam, ever happy answer talking Good my from think the mice

you it had by diet these high-fat no study the It's days, weeks did. or mice -- feeding mouse for have IL XX olden them obese competitor mice. longer. pretty a a the study, from In so to Again, you there's really learnings so generate that was standard

these shelf. off are Nowadays, the

these mice. in buy diet can obese You mice obese

In endpoints. body terms on In case, look obviously, trials skin. weight, liver so is loss, points, done of at we weight I looking and this mentioned body before, -- perhaps different as endpoint, primary these at before, effects have the secondary end the we weight,

look We at steatosis. lipids, do we're doing liver. dexa look have we -- liver at in We study the staining also in the

So everything read well. want weight that you would to the as there loss out post

Really, again, need into before, what said like It's individual I or a how you translates from to at one-to-one the look understand potentially translates not to it study readings you expect in humans. correlation.

for These number models of are used things. a

being used They've see DPP-X them You'll for for agonist. for They've they've for inhibitors, developing GLP-X used used diabetes. drugs been used for been SGLTX. been

NLRPX. we're Now at looking

take a So see in model, can human it's to and model what then individual on you you study, a would really this pieces reconstruct broad and right? want

excited we're model for This the us again, And just humans. just a model. is to about this path not into go

actively then And And on study. link We'll to meantime, the downstream. so the a with few in on hypothalamic in the biologists human get weeks understanding are the and NLRPX interaction and effects you to we'll models. in data the trying our complete dots

to picture. try a just build So

Samuel Slutsky

on just That's prevention real potential MACE And Okay. in on pericarditis of helpful. quick study. XXXX the

in XXXX about kind unmet landscape of need You do paradigm, slotting where best the see in? you that just currently profile think of

Raju Mohan

Yes.

lot it. We've Marty. talked about have a me Let

for this you. articulate Let Marty Marty?

Martin Auster

sure, Sam. Yes,

in of cardiovascular of disease. So obviously, some there's the evolution management some

XXXX. developing And that that the will course we're so mature sort of over time

to perfect recurrent Rilonacept's of may a therapeutic an sort very with therapeutic. nature sort therapeutics. Currently, It's the patients. classic manage pretty orphan you for is less of injectable your really pericarditis, options. refractory a some limited your niche go-to than due be have obviously It's expensive patients its indication to also on for think I difficult

put oral [indiscernible] symptoms. steroids often and option aspirin managed like people an opportunity patients of with in recurrent think, a use a now suffering guidelines scattered treatment sort who and for and consistency that that. some things pericarditis of approach There's with think and like lot are to, bit of things is necessarily disease certainly I a without more forth I And

role. in the And the I as biologics by clinical an is setting. inhibitor, think XXXX could de-risked of nice targeted very important IL-X-driven obviously, success heavily a NLRPX play pathway such And the

and right of that in for to that paradigm. develop treatment excited find the the filing So kind [ ]

Operator

you. Thank

further at over now We back remarks. this any or additional turn closing presentation have I for time. Dr. the no to Raju questions Mohan

Raju Mohan

you Yes. to Yes. Thank Thank you, all the call. on everybody.

interest back us. at reporting we the your to for months, mice connecting exciting Ventyx. forward -- with looking you Phase on with the conference look towards partnerships forward and reporting We efforts period connecting in a the very So hopefully thank you XXX data. We're then continued Obviously, with in investor on Crohn's and for III to moving you about our coming the trial, talking coming and on ongoing trial. the

again, But today, So the talk about. a and lot you to thank for all, thank to you team.

Operator

participation. Thank you, everyone. appreciate This concludes We your today's teleconference.

disconnect. may You

Ventyx Biosciences (VTYX) 9 May 242024 Q1 Earnings call transcript